FAKTOR-OPTIONSSCHEIN - ZEALAND PHARMA | Delayed Börse Stuttgart 11:12:35 2024-06-06 EDT | ||
| 8.28 EUR | -11.73% |
|
| Current month | +7.82% | ||
| 1 month | -4.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-06 | 8.28 | -11.73% |
| 24-06-05 | 9.38 | -0.21% |
| 24-06-04 | 9.4 | +10.85% |
| 24-06-03 | 8.48 | -2.53% |
| 24-05-31 | 8.7 | -8.32% |
Delayed Quote Börse Stuttgart
Last update June 06, 2024 at 11:12 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | MG1VGP |
| ISIN | DE000MG1VGP6 |
| Date issued | 2024-04-08 |
| Strike | 915.7 kr |
| Maturity | Unlimited |
| Parity | 4.25 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.05 € |
|---|---|
| Lowest since issue | 8.28 € |
| Spread | 0.2 € |
| Spread % | 2.36% |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
610.5
DKK
Average target price
785.6
DKK
Spread / Average Target
+28.68%
- Stock Market
- Certificates
- Certificat
